Use of Human Blood Samples in Leukocyte Functional Assays
Research type
Research Study
Full title
Use of Human Blood Samples in Leukocyte Functional Assays
IRAS ID
211866
Contact name
Simon Dovedi
Contact email
Sponsor organisation
MedImmune
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
The cells of the immune system are important in the progression of many diseases and a growing body of recent research indicates that several biological therapeutics can modify or utilise components of the immune system as part of their activity. At MedImmune, as a company dedicated to the discovery of new biological therapies that help patients live healthier, longer and more satisfying lives, it is essential that we are able to investigate novel mechanisms of disease that are of relevance to therapy areas and characterise the way in which our potential therapies affect the behaviour of the immune system. This is key as it will allow us a greater understanding of the diseases we are studying and it will allow us to establish how our drugs influence specific disease mechanisms. An essential step in this characterisation is the assessment of potential therapeutics and targets in a number of in vitro and in vivo assays that use primary blood cells and blood components. The aim of this program is to use whole blood, blood constituents or isolated blood cell subsets, obtained from employees of MedImmune, in a variety of in vitro (and in vivo) assays to investigate novel disease mechanism or to establish the efficacy and mechanisms of action of potential therapies. The blood and blood derivatives from the internal blood donor panel will be used for research purposes only and will not be used in drug trials.
REC name
East of England - Cambridge East Research Ethics Committee
REC reference
17/EE/0461
Date of REC Opinion
28 Nov 2017
REC opinion
Favourable Opinion